Treatment for chronic methicillin-sensitive Staphylococcus aureus pulmonary infection in people with cystic fibrosis (Q24186014)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27003247%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Molla I Ahmed

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27003247%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

1 June 2020

publication date

22 March 2016

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27003247%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27003247%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

CD011581

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27003247%20AND%20SRC:MED&resulttype=core&format=json

Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

A cohort study of the Copenhagen CF Centre eradication strategy against Staphylococcus aureus in patients with CF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Pharmacokinetics of ciprofloxacin in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Pharmacokinetics and safety of MP-376 (levofloxacin inhalation solution) in cystic fibrosis subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

A placebo-controlled trial of cephalexin therapy in the ambulatory management of patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Unorthodox long-term aerosolized ampicillin use for methicillin-susceptible Staphylococcus aureus lung infection in a cystic fibrosis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Altered steady state pharmacokinetics of levofloxacin in adult cystic fibrosis patients receiving calcium carbonate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Pharmaceutical intervention in the care of cystic fibrosis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

An in vivo assessment of the tobramycin/ticarcillin interaction in cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Update in cystic fibrosis 2006

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Impact of Staphylococcus aureus on the pathogenesis of chronic cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Diagnosing and managing infection in CF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Nasal Staphylococcus aureus carriage is not a risk factor for lower-airway infection in young cystic fibrosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Prophylactic antibiotics in cystic fibrosis: a conviction without evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Prophylactic anti-staphylococcal antibiotics for cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Antibiotic treatment of Staphylococcus aureus infection in cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Staphylococcus aureus in early cystic fibrosis lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

Effect of continuous antistaphylococcal therapy on the rate of P. aeruginosa acquisition in patients with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

Single-dose pharmacokinetics of oral ciprofloxacin in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

A controlled trial of nebulized aminoglycoside and oral flucloxacillin versus placebo in the outpatient management of children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

The prevalence of cystic fibrosis in the European Union

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

Genetics of cystic fibrosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

[Aminoglycosides in patients with mucoviscidosis and pulmonary exacerbation. Comparison of once or three times daily administration]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011581.PUB2

7 January 2021

10.1002/14651858.CD011581.PUB2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27003247%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference